Shots:

• The P-III (MAESTRO-NAFLD-1) trial evaluates resmetirom (100/80mg, qd) vs PBO in a ratio (1:1:1) in 1200 patients with NAFLD for 52wks. The results which were expected in YE 2021, now expected in Jan 2022
• The 1EPs of the study is to evaluate the safety & tolerability of resmetirom & 2EPs include LDL-cholesterol, apolipoprotein B, TG lowering & reduction of liver fat as determined by MRI-PDFF. Additionally, exploratory EPs will be evaluated including a reduction in liver enzymes, FibroScan scores, other fibrosis & inflammatory biomarkers
• The therapy is also being evaluated in the P-III (MAESTRO-NASH) study in a ratio (1:1:1) in 900 patients with liver biopsy-confirmed NASH

Ref: Globe Newswire | Image: Madrigal